These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29483097)

  • 1. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.
    He L; Tang J; Andersson EI; Timonen S; Koschmieder S; Wennerberg K; Mustjoki S; Aittokallio T
    Cancer Res; 2018 May; 78(9):2407-2418. PubMed ID: 29483097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
    Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
    Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
    Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS
    Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network Propagation Predicts Drug Synergy in Cancers.
    Li H; Li T; Quang D; Guan Y
    Cancer Res; 2018 Sep; 78(18):5446-5457. PubMed ID: 30054332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer.
    Jaiswal A; Yadav B; Wennerberg K; Aittokallio T
    Methods Mol Biol; 2019; 1888():205-217. PubMed ID: 30519949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.
    Ianevski A; Timonen S; Kononov A; Aittokallio T; Giri AK
    PLoS Comput Biol; 2020 Feb; 16(2):e1007604. PubMed ID: 32012154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratification and prediction of drug synergy based on target functional similarity.
    Yang M; Jaaks P; Dry J; Garnett M; Menden MP; Saez-Rodriguez J
    NPJ Syst Biol Appl; 2020 Jun; 6(1):16. PubMed ID: 32487991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.
    Berlow NE; Rikhi R; Geltzeiler M; Abraham J; Svalina MN; Davis LE; Wise E; Mancini M; Noujaim J; Mansoor A; Quist MJ; Matlock KL; Goros MW; Hernandez BS; Doung YC; Thway K; Tsukahara T; Nishio J; Huang ET; Airhart S; Bult CJ; Gandour-Edwards R; Maki RG; Jones RL; Michalek JE; Milovancev M; Ghosh S; Pal R; Keller C
    BMC Cancer; 2019 Jun; 19(1):593. PubMed ID: 31208434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.
    Malyutina A; Majumder MM; Wang W; Pessia A; Heckman CA; Tang J
    PLoS Comput Biol; 2019 May; 15(5):e1006752. PubMed ID: 31107860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
    Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
    PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
    Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
    Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer.
    Jaeger S; Igea A; Arroyo R; Alcalde V; Canovas B; Orozco M; Nebreda AR; Aloy P
    Cancer Res; 2017 Jan; 77(2):459-469. PubMed ID: 27879272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL).
    Ozpuyan F; Meyer P; Ni H; Al-Masri H; Alkan S
    Leuk Lymphoma; 2007 Nov; 48(11):2247-50. PubMed ID: 17990182
    [No Abstract]   [Full Text] [Related]  

  • 16. Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia.
    Brothers J; Castillo DR; Jeon WJ; Joung B; Linhares Y
    Hematology; 2023 Dec; 28(1):2237342. PubMed ID: 37485976
    [No Abstract]   [Full Text] [Related]  

  • 17. Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms.
    Axelrod M; Gordon VL; Conaway M; Tarcsafalvi A; Neitzke DJ; Gioeli D; Weber MJ
    Oncotarget; 2013 Apr; 4(4):622-35. PubMed ID: 23599172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.
    Guest ST; Kratche ZR; Irish JC; Wilson RC; Haddad R; Gray JW; Garrett-Mayer E; Ethier SP
    Oncotarget; 2016 Jun; 7(24):36138-36153. PubMed ID: 27153554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells.
    Athanasiadis P; Ianevski A; Skånland SS; Aittokallio T
    Methods Mol Biol; 2022; 2449():327-348. PubMed ID: 35507270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.